Get notified when RNAZ files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Critical incident detected

Existential event

Time-sensitive event — see the red-flag panel below for the source-quoted detail.

Red Flags Detected

  • Debt Default (new) — Convertible notes contain multiple default triggers including payment defaults, cross-defaults over $500K, and late SEC filings that increase interest to 18%.
NASDAQ: RNAZ Transcode Therapeutics, Inc. 8-K

Transcode secures $14M equity line and $6M convertible notes with Yorkville at steep discounts

Filed April 7, 2026 · Period ending April 6, 2026 · ~2 min read

Key Changes

  • high

    Company obtained $14M standby equity line and $6M in convertible notes from Yorkville, but notes convert at 5% discount with floor price protection creating significant dilution risk if stock declines. Net proceeds from notes total $5.7M after discounts.

  • high

    Initial capital access capped at 183,301 shares (19.99% of outstanding) per Nasdaq rules. Company must obtain shareholder approval via proxy vote to access full $14M commitment and convert entire $6M in notes.

  • high

    Convertible notes contain multiple default triggers including late SEC filings, trading suspensions over 10 days, and cross-defaults exceeding $500K. Upon default, interest jumps from 5% to 18% and Yorkville can demand immediate repayment plus 10% premium.

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.

Partner

Trade RNAZ commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify